News News

Sirnaomics’ President and CEO Patrick Lu Gives Keynote Address at the 7th RNAi China Conference

October 10, 2019.

Sirnaomics Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced that President and CEO Patrick Lu, PhD, delivered a keynote address at the 7th RNAi China Conference on October 10 at 11:05 AM Beijing Time.

Lu Speech 03
Dr. Patrick Lu

In a presentation titled “Novel siRNA Therapeutics for Enhancing Antitumor Activity of Immune Checkpoint Inhibitor”, Dr. Lu shared an overview of Sirnaomics’ differentiated RNAi technology platform, which leverages its proprietary polypeptide nanoparticle (PNP) drug delivery system to optimize the delivery of siRNA drugs into the tumor microenvironment and an array of liver cell types implicated in the progression of liver cancer and liver fibrosis.

Sirnaomics’ STP705 currently is being evaluated in Phase 2 clinical trials for treatment of non-melanoma skin cancer and has received Orphan Drug Designation from the US FDA for liver cancer and liver fibrosis.

Lu Speech 01
Dr. Lu speaks at RNAi China Conference

About Sirnaomics, Inc.

Sirnaomics, Inc., a leading privately held clinical-stage biopharmaceutical company engaged in the discovery and development of RNAi therapeutics, is headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The Company’s mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in the USA and China. The Company is supported by funding from institutional investors and corporate partnerships. Sirnaomics has developed a strong portfolio of intellectual property with the freedom to operate and develop an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at www.sirnaomics.com.

CONTACT:

Westwicke Healthcare 
Investors:
Stephanie Carrington
Tel: +1 646 277 1282 
Email: Stephanie.Carrington@icrinc.com
Media:
Mark Corbae  
Tel: +1 203 682 8288  
Mark.Corbae@icrinc.com

SOURCE Sirnaomics, Inc.

Read Original News

About Sirnaomics, Inc.

Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The Company’s mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The company is supported by funding from institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at www.sirnaomics.com.